# How to Make Long-Lasting Injections for Multiple Sclerosis Treatment

> A patent for a slow-release version of the MS drug glatiramer acetate, designed to be injected once every week to six months instead of daily.

- **Patent:** US RE50301
- **Original title:** USRE50301E1 - Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
- **Owner:** Mapi Pharma Ltd
- **Granted:** 2025
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical

## What it does

This patent describes a way to package the drug glatiramer acetate—commonly used for multiple sclerosis—into a 'depot' form. Instead of the drug being absorbed by the body all at once, it is trapped inside a carrier material, such as biodegradable microspheres made of polymers like PLGA. This allows the medication to be released slowly into the patient's system over a period ranging from one week to six months. By using a double-emulsification process, the drug is kept in an internal phase that gradually leaks out, aiming to maintain therapeutic levels in the blood without the need for daily injections.

## What it does NOT cover

- Does not cover the chemical structure of glatiramer acetate itself, which is a known drug.
- Does not cover immediate-release formulations that are injected daily.
- Does not cover non-depot delivery methods like oral pills or intravenous drips.
- Does not cover specific medical devices or needles used to deliver the injection.

## The clever bit

The innovation lies in stabilizing a complex mixture of amino acids (glatiramer) within a polymer matrix to ensure it releases steadily over months without degrading or losing its therapeutic effectiveness.

## Real-world examples

1. Experimental long-acting glatiramer acetate depot injections
2. Slow-release polymer-based drug delivery systems for autoimmune diseases

## Why it matters

Glatiramer acetate is a standard treatment for multiple sclerosis, but it traditionally requires painful daily injections. This patent represents a significant effort to improve patient compliance and quality of life by reducing the frequency of dosing. If successful, it could shift the market standard from daily self-administration to infrequent clinical visits.

## Frequently asked questions

### What does How to Make Long-Lasting Injections for Multiple Sclerosis Treatment cover?

A patent for a slow-release version of the MS drug glatiramer acetate, designed to be injected once every week to six months instead of daily.

### Who owns patent US RE50301?

Mapi Pharma Ltd owns this patent, granted in 2025.

### When does this patent expire?

This patent is expected to expire on February 18, 2045, when the invention enters the public domain.

### What problem does this patent solve?

Glatiramer acetate is a standard treatment for multiple sclerosis, but it traditionally requires painful daily injections. This patent represents a significant effort to improve patient compliance and quality of life by reducing the frequency of dosing. If successful, it could shift the market standard from daily self-administration to infrequent clinical visits.

### What does this patent NOT cover?

Does not cover the chemical structure of glatiramer acetate itself, which is a known drug.

**Full plain-English explainer:** https://patentbrief.org/patent/us/RE50301/temperature-controlled-mug

**Original patent:** https://patents.google.com/patent/USRE50301

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._